Jun 25 |
VBI Vaccines Announces Results of Annual General Meeting
|
May 29 |
VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
|
May 22 |
VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients
|
May 15 |
VBI Vaccines GAAP EPS of -$0.73 misses by $0.20, revenue of $1.21M misses by $1.64M
|
May 15 |
VBI Vaccines Reports First Quarter 2024 Financial Results
|
Apr 16 |
VBI Vaccines FY Non-GAAP EPS of $3.96
|
Apr 16 |
VBI Vaccines Reports Full Year 2023 Financial Results
|
Apr 11 |
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
Apr 9 |
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
Apr 9 |
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
|